AbbVie Inc. $ABBV Shares Acquired by Hamilton Wealth LLC

Hamilton Wealth LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 201.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,960 shares of the company’s stock after buying an additional 44,736 shares during the quarter. AbbVie comprises approximately 1.0% of Hamilton Wealth LLC’s holdings, making the stock its 28th largest position. Hamilton Wealth LLC’s holdings in AbbVie were worth $14,563,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. grew its position in shares of AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. State Street Corp lifted its position in AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after purchasing an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC boosted its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE boosted its stake in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the period. Finally, Norges Bank bought a new position in AbbVie in the 4th quarter worth about $5,865,055,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Up 0.1%

ABBV stock opened at $263.58 on Thursday. The firm’s 50-day moving average is $237.54 and its two-hundred day moving average is $223.60. The company has a market capitalization of $465.69 billion, a price-to-earnings ratio of 129.84, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. AbbVie Inc. has a 52 week low of $187.62 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the firm posted $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. On average, equities research analysts predict that AbbVie Inc. will post 14.14 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Union approved RINVOQ for adults and adolescents aged 12 and older with severe alopecia areata. The decision was supported by Phase 3 data showing statistically significant scalp, eyebrow and eyelash hair regrowth, including complete scalp regrowth for some patients. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo in patients 12 and older who are candidates for systemic therapy. AbbVie described it as the first and only systemic treatment approved in the EU for this condition, creating another potential revenue opportunity for the drug. RINVOQ vitiligo approval
• Positive Sentiment: The approvals reinforce investor expectations that RINVOQ and Skyrizi can continue replacing Humira as AbbVie’s primary growth engines. The two drugs have been highlighted as key drivers ahead of earnings, while AbbVie’s long dividend-raise record supports its appeal to income-focused investors.
• Positive Sentiment: Unusual options activity showed investors purchasing approximately 19,745 call contracts, about 18% above average call volume. This indicates increased bullish positioning, although options activity is not a guarantee of future performance.
• Neutral Sentiment: Erste Group raised its 2027 EPS forecast for AbbVie to $16.40 from $16.27 but slightly lowered its 2026 estimate to $14.05 from $14.08, leaving the near-term earnings outlook mixed.
• Negative Sentiment: After a strong multiyear rally, valuation concerns and the possibility of “sell the news” volatility could limit further gains, particularly if second-quarter results or guidance do not exceed elevated expectations.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. HSBC reaffirmed a “buy” rating and set a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Finally, BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $269.29.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.